enGene Holdings Inc. (NASDAQ:ENGNW – Get Free Report) shares traded down 15.9% on Wednesday . The company traded as low as $0.81 and last traded at $0.95. 8,493 shares were traded during mid-day trading, an increase of 82% from the average session volume of 4,656 shares. The stock had previously closed at $1.13.
enGene Stock Down 10.7 %
The stock’s 50 day simple moving average is $1.19 and its two-hundred day simple moving average is $1.33.
enGene Company Profile
enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.
Featured Stories
- Five stocks we like better than enGene
- What is MarketRank™? How to Use it
- Top Growth Picks: 3 Low-Cost Stocks That Could Double in Value
- What to Know About Investing in Penny Stocks
- Is Johnson & Johnson Stock Set to Reward Long-Term Holders?
- What Is WallStreetBets and What Stocks Are They Targeting?
- Buffett’s Sale of BAC Stock: A Smart Move or Missed Opportunity?
Receive News & Ratings for enGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for enGene and related companies with MarketBeat.com's FREE daily email newsletter.
